C4 Therapeutics (United States)
company in Watertown, United States
CCCC Nasdaq
SEC CIK 1662579
Follow C4 Therapeutics (United States)
Weekly email: filings, results
Revenue, last quarter
$8.5M
−24.6% vs same quarter last year
Net income
−$21.8M
+32.1% vs same quarter last year
EPS, diluted
−$0.16
+63.6% vs same quarter last year
Operating cash flow
−$26M
+16.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $35.9M | −$105M |
| FY24 | $35.6M | −$105.3M |
| FY23 | $20.8M | −$132.5M |
| FY22 | $31.1M | −$128.2M |
| FY21 | $45.8M | −$83.9M |
| FY20 | - | −$66.3M |
| FY19 | - | −$34.1M |
| FY18 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −320.5% | −292.1% |
| FY24 | −336.1% | −296% |
| FY23 | −669.8% | −638.3% |
| FY22 | −416.6% | −412.2% |
| FY21 | −179.4% | −183.2% |
| FY20 | - | - |
| FY19 | - | - |
| FY18 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$99.3M |
| FY24 | −$65.3M |
| FY23 | −$108.5M |
| FY22 | −$111.4M |
| FY21 | −$88.2M |
| FY20 | −$67.9M |
| FY19 | $54.3M |
| FY18 | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $193K |
| FY24 | $194K |
| FY23 | $110K |
| FY22 | $0 |
| FY21 | - |
| FY20 | $194K |
| FY19 | $30K |
| FY18 | - |
- C4 Therapeutics (United States)
- Healthcare median
Show the numbers
| Year | C4 Therapeutics (United States) | Healthcare median |
|---|---|---|
| FY25 | −292.1% | −30.6% |
| FY24 | −296% | −47% |
| FY23 | −638.3% | −58% |
| FY22 | −412.2% | −80.4% |
| FY21 | −183.2% | −71.8% |
| FY20 | - | −62.2% |
| FY19 | - | −46.2% |
| FY18 | - | −49.6% |